Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 7:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bone Age Clear all
Completed Phase 1Phase 2 Interventional Results available

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

NCT00691938
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
LBH589, Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 13, 2026, 7:43 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191
View directory record Official record
Conditions
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Interventions
Asciminib, Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
9
States / cities
Denver, Colorado • Peoria, Illinois • Saint Paul, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 13, 2026, 7:43 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

NCT06934967
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Atlanta, Georgia • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Phase 2 Interventional

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00004217
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, valspodar
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
89
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

NCT03316521
View directory record Official record
Conditions
Complement Mediated Diseases
Interventions
AMY-101
Drug
Lead sponsor
Amyndas Pharmaceuticals S.A.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 13, 2026, 7:43 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for Age-Related Frailty

NCT05284604
View directory record Official record
Conditions
Frailty
Interventions
Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Potassium Citrate to Prevent Age Related Bone Loss

NCT00282126
View directory record Official record
Conditions
Osteoporosis
Interventions
Potassium citrate
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Spica Casting in Pediatric Femur Fractures: Study of Single Leg Versus Double Leg Spica Casts

NCT01293916
View directory record Official record
Conditions
Femur Fracture
Interventions
Spica casting
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 6 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 13, 2026, 7:43 AM EDT
Recruiting Phase 2 Interventional

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

NCT05554406
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
215
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

NCT00895934
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions
vorinostat, gemtuzumab ozogamicin, azacitidine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Stanford, California • Bremerton, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00093470
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia
Interventions
Clinical Observation, Tipifarnib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
339
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 228 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 13, 2026, 7:43 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Use of Complementary and Alternative Medicine Among Older Mexican Americans

NCT00084110
View directory record Official record
Conditions
Arthritis, Diabetes Mellitus, Fractures, Hypertension, Depression, Urinary Incontinence
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2000
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 13, 2026, 7:43 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00658814
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Gemtuzumab Ozogamicin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
177
States / cities
Burbank, California • Palo Alto, California • Sacramento, California + 122 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

NCT03512262
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis, Osteoporosis Senile, Osteoporosis of Vertebrae
Interventions
Abaloparatide, Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 85 Years · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Greenbrae, California • Simi Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

NCT01106651
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 80 Years
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 13, 2026, 7:43 AM EDT
Terminated Not applicable Interventional Results available

Intraoperative Methadone vs Morphine for Postoperative Pain Control in Patients Undergoing Surgery of the Tibia

NCT01430182
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Methadone, Morphine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 13, 2026, 7:43 AM EDT
Terminated Phase 3 Interventional Results available

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

NCT02352753
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 13, 2026, 7:43 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Biological and Behavioral Outcomes of Community Nature Walks

NCT06056375
View directory record Official record
Conditions
Stress, Psychological, Telomere Shortening, Stress Reaction
Interventions
Reclaiming Nature Intervention
Behavioral
Lead sponsor
Charlotte Tate
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400
View directory record Official record
Conditions
Osteoporosis, Age-Related
Interventions
Atenolol, Nebivolol, Propranolol, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Phase 2 Interventional

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

NCT00195000
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Mylotarg, Cytarabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 13, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02085408
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Daunorubicin, Cytarabine, Clofarabine, Decitabine, Observation, Allogeneic hematopoietic stem cell transplantation
Drug · Other · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
60 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
266
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 181 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 13, 2026, 7:43 AM EDT
Active, not recruiting Phase 4 Interventional

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

NCT05151484
View directory record Official record
Conditions
Age-Related Osteoporosis
Interventions
Teriparatide, Alendronate
Drug
Lead sponsor
Madhumathi Rao
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 13, 2026, 7:43 AM EDT
Recruiting No phase listed Observational

Genetic Regulators of Bone Health That Are Unique to Vertebral Bone

NCT05946278
View directory record Official record
Conditions
Age-Related Osteoporosis
Interventions
Sample collection for gene expression
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 13, 2026, 7:43 AM EDT
Not listed Phase 3 Interventional Results available

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 59 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
170
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 13, 2026, 7:43 AM EDT